

Roger Gunnarsson resigns as board member due to return to a full-time investment banking career, which precludes him from holding board position in FluoGuide

Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a biotech company specializing in precision cancer surgery, announces that Roger Gunnarsson will resign from his position as member of the board of directors in FluoGuide, effective 31 October 2023.

Roger returns to his previous career in healthcare investment banking. Due to the demand of his new, full-time position, he is required to step down as board of director in FluoGuide.

“Roger’s commitment and expertise have been invaluable, particularly in respect of partnering structures, and although his short service his participation was probably the most important point in time for FluoGuide,” said Peter Mørch Eriksen, Chairman of the board of directors of FluoGuide, and continues *“We wish him all the best in his new role.”*

The Board will not replace Roger for now but will review the Board composition during the annual nomination committee process.

Certified Adviser:

Svensk Kapitalmarknadsgranskning AB
Phone: +46 70 755 95 51
E-mail: ca@skmg.se

For further information, please contact:

Morten Albrechtsen, CEO
FluoGuide A/S
Phone: +45 24 25 62 66
E-mail: ma@fluoguide.com

About FluoGuide

FluoGuide is a biotech company specializing in precision cancer surgery. FluoGuide's lead product, FG001, is designed to enhance surgical accuracy by illuminating cancer cells intraoperatively using fluorescent light, which binds to the uPAR receptor, widely expressed in most solid cancer types. It is anticipated that FG001 will decrease both the incidence of local recurrence after surgery and surgical complications, improving cancer treatment and outcomes for patients, while also reducing healthcare costs. Moreover, FluoGuide's technology platform may also be utilized for photothermal therapy (PTT), which kills cancer cells through heating them with the use of near-infrared light. A technique that spares healthy surrounding tissue from damage, offering a direct therapeutic effect of FG001, further benefiting patients undergoing cancer surgery.

FluoGuide is listed on the Nasdaq First North Growth Market in Stockholm under the ticker symbol "FLUO". For more information about FluoGuide's pipeline, technology, and upcoming events, visit www.fluoguide.com

Attachments

[Roger Gunnarsson resigns as board member due to return to a full-time investment banking career, which precludes him from holding board position in FluoGuide](#)